Skip to content
ES

Less noise. More signal.

Context · Geopolitics · sweep Tuesday, November 17, 2026

GLP-1 race for obesity: Lilly against Novo Nordisk and the direct channel

Competition between Eli Lilly and Novo Nordisk for the GLP-1 obesity drug market shifts from clinical efficacy to distribution: head-to-head results for retatrutide and CagriSema, regulatory approvals in the EU and direct-to-consumer models that bypass pharmacies and telemedicine. Public capital validates the thesis with Lilly at all-time highs and Novo raising forecasts, while marketing litigation and conflicts of interest with Oura expose the regulatory fragility of the channel. It matters because the regulatory and distribution layer defines who captures the margin of a therapeutic category that reconfigures public health, insurance and consumption.

Title, thesis and gravity assessment written by an AI model, without prior human review.

Gravity72/100 · Context
Why this gravity
Phase 3 clinical trial of retatrutide shows superiority over Ozempic in weight loss and glycemic control, and the EMA's CHMP backs Lilly's oral pill. Material data TODAY for competitive repositioning in GLP-1, although without final approval or full regulatory disruption.
— Assessment by the Semantic Gravity Engine
Coverage
4 feeds · 4 independent publisher groups (corroborated)
Cross verticals
Geopolitics, Lifespan & Healthspan, Investing
Gravity vs. the previous edition
+17 (55 → 72)

coverage, not accuracy

First detected Thu, Oct 29 · 20 days trackedGravity evolution
Lead source
Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trial - Reuters · Reuters Legal
Actors: Eli Lilly · Novo Nordisk · Hims & Hers · Oura · EMA · STAT+
Timeline · Madrid time
  1. 15:58
  2. 17:31
  3. 18:30
  4. 11:45
  5. 14:42
  6. 17:38
  7. 14:37
  8. 11:29
  9. 16:19
  10. 15:30
  11. 19:04
  12. 22:07
  13. 10:30
  14. 18:03
ShareWhatsApp
Related stories